Notably, these results were further corroborated by cBioPortal data, which showed that AML patients (n = 25) with high mRNA expression of the genes upregulated by EVAML in our cohort (namely, CAB39, ADA, SLC2A14, CHMP2A, NAT8L, GPX4, CTCF, TPX2, NDUFS8, STAT3, FANCD2 and BRCA1) had decreased OS compared to unaltered AML patients (n = 148) (log-rank, p < 0.04) (Supplementary Fig. 8d, e). This evidence concerns the gene CHMP2A and acute myeloid leukemia.